To include your compound in the COVID-19 Resource Center, submit it here.

AnaptysBio's ANB020 meets objective in Phase IIa for atopic dermatitis

AnaptysBio Inc. (NASDAQ:ANAB) said lead program ANB020, an antibody against IL-33, “achieved the trial protocol objective” in a Phase IIa trial to treat moderate to

Read the full 256 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE